Drug-related nephrotoxic and ototoxic reactions: A link through a predictive mechanistic commonality

Drug Safety

Volumn 31, Issue 10, 2008, Pages 877-884

  Verdel, Bertha Maria ^a   Van Puijenbroek, Eugène P ^b   Souverein, Patrick C ^a   Leufkens, Hubert G M ^a   Egberts, Antoine C G ^a,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NETHERLANDS PHARMACOVIGILANCE CENTRE LAREB   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Adverse drug reactions; Ear disorders, drug induced; Kidney disorders, drug induced

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CALCIUM ANTAGONIST; CARBONATE DEHYDRATASE INHIBITOR; CORTICOSTEROID; DIGITALIS; DIURETIC AGENT; GLUCOCORTICOID; ION CHANNEL; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; QUININE; SALICYLIC ACID DERIVATIVE; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT;

ARTICLE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SURVEILLANCE PROGRAM; HEARING LOSS; HOMEOSTASIS; HUMAN; INNER EAR; INNER EAR DISEASE; KIDNEY PARENCHYMA; NEPHROTOXICITY; NETHERLANDS; OTOTOXICITY; POTASSIUM TRANSPORT; PRIORITY JOURNAL; SODIUM TRANSPORT; TINNITUS; VERTIGO;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AMINOGLYCOSIDES; CINCHONA ALKALOIDS; DATABASES, FACTUAL; DIURETICS; HEARING DISORDERS; HEARING LOSS; HUMANS; KIDNEY FAILURE; LABYRINTH DISEASES; NETHERLANDS; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PRESCRIPTION DRUGS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; TIME FACTORS; TINNITUS; UROLOGIC DISEASES; VASODILATOR AGENTS; VERTIGO;

EID: 50649114380     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831100-00006     Document Type: Article

References (40)

1. Seligmann H, Podoshin L, Ben-David J, et al. Drug-induced tinnitus and other hearing disorders. Drug Saf 1996; 14: 198-212
2. Palomar Garcia V, Abdulghani Martinez F, Bodet Agusti FE, et al. Drug-induced otoxicity: current status. Acta Otolaryngol 2001; 121: 569-72
3. Lee CA, Mistry D, Uppal S, et al. Otologic side effects of drugs. J Laryngol Otol 2005; 119: 267-71
4. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on repeated dose toxicity [report no. CPMP/SWP/1042/99 corr.]. London: European Agency for the Evaluation of Medical Products, 2000
5. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on safety pharmacology studies for human pharmaceuticals [report no. CPMP/ICH/539/00]. London: European Agency for the Evaluation of Medical Products, 2000
6. Center for Drug Evaluation and Research (CDER). Guidance for industry: S7A safety pharmacology studies for human pharmaceuticals. Rockville (MD): Food and Drug Administration, 2001
7. Arslan E, Orzan E, Santarelli R. Global problem of drug-induced hearing loss. Ann N Y Acad Sci 1999; 884: 1-14
8. Vasquez R, Mattucci KF. A proposed protocol for monitoring ototoxicity in patients who take cochleo- or vestibulotoxic drugs. Ear Nose Throat J 2003; 82: 181-4
9. Walker Jr EM, Fazekas-May MA, Bowen WR. Nephrotoxic and ototoxic agents. Clin Lab Med 1990; 10: 323-54
10. Black FO, Pesznecker SC. Vestibular ototoxicity: clinical considerations. Otolaryngol Clin North Am 1993; 26: 713-36
11. Izzedine H, Tankere F, Launay-Vacher V, et al. Ear and kidney syndromes: molecular versus clinical approach. Kidney Int 2004; 65: 369-85
12. Thodi C, Thodis E, Danielides V, et al. Hearing in renal failure. Nephrol Dial Transplant 2006; 21: 3023-30
13. Arnold W. Inner ear and renal diseases. Ann Otol Laryngol 1984; 112: S119-24
14. Lang F, Vallon V, Knipper M, et al. Functional significance of channels and transporters expressed in the inner ear and kidney. Am J Physiol Cell Physiol 2007; 293: C1187-208
15. Hunter M. Accessory to kidney disease. Nature 2001; 414: 502-3
16. Peters TA, Monnens LA, Cremers CW, et al. Genetic disorders of transporters/channels in the inner ear and their relation to the kidney. Pediatr Nephrol 2004; 19: 1194-201
17. World Health Organization. Anatomical Therapeutic Chemical (ATC) classification index. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 1994
18. van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11: 3-10
19. Lee JH, Marcus DC. Estrogen acutely inhibits ion transport by isolated stria vascularis. Hear Res 2001; 158: 123-30
20. Liu J, Marcus DC, Kobayashi T. Inhibitory effect of erythromycin on ion transport by stria vascularis and vestibular dark cells. Acta Otolaryngol 1996; 116: 572-5
21. Lumley CE, Walker SR, Hall GC, et al. The under-reporting of adverse drug reactions seen in general practice. Pharmaceut Med 1986; 1: 205-12
22. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29: 385-96
23. Milstien JB, Faich GA, Hsu JP, et al. Factors affecting physician reporting of adverse drug reactions. Drug Inf J 1986; 20: 157-64
24. Martin RM, Kapoor KV, Wilton LV, et al. Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study. BMJ 1998; 317: 119-20
25. De Bruin ML, Pettersson M, Meyboom RH, et al. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 2005; 26: 590-7
26. Humes HD. Insights into ototoxicity: analogies to nephrotoxicity. Ann N Y Acad Sci 1999; 884: 15-8
27. Tran BH. Endolymphatic deafness: a particular variety of cochlear disorder. ORL J Otorhinolaryngol Relat Spec 2002; 64: 120-4
28. Ikeda K, Oshima T, Hidaka H, et al. Molecular and clinical implications of loop diuretic ototoxicity. Hear Res 1997; 107: 1-8
29. Stypulkowski PH. Mechanisms of salicylate ototoxicity. Hear Res 1990; 46: 113-45
30. Prepageran N, Rutka JA. Salicylates, nonsteroidal anti-inflammatory drugs, quinine, and heavy metals. In: Roland PS, Rutka JA, editors. Ototoxicity. Hamilton (ON): BC Decker Inc., 2004: 29-41
31. Takeuchi S, Ando M. Inwardly rectifying K+ currents in intermediate cells in the cochlea of gerbils: a possible contribution to the endocochlear potential. Neurosci Lett 1998; 247: 175-8
32. 2+ conductances in hair cells. Hear Res 2004; 195: 67-74
33. Curtis LM, ten Cate WJ, Rarey KE. Dynamics of Na,K-ATPase sites in lateral cochlear wall tissues of the rat. Eur Arch Otorhinolaryngol 1993; 250: 265-70
34. Pondugula SR, Sanneman JD, Wangemann P, et al. Glucocorticoids stimulate cation absorption by semicircular canal duct epithelium via epithelial sodium channel. Am J Physiol Renal Physiol 2004; 286: F1127-35
35. Herman P, Tan CT, van den Abbeele T, et al. Glucocorticosteroids increase sodium transport in middle ear epithelium. Am J Physiol 1997; 272: C184-90
36. Marcotti W, van Netten SM, Kros CJ. The aminoglycoside antibiotic dihydrostreptomycin rapidly enters mouse outer hair cells through the mechano-electrical transducer channels. J Physiol 2005; 567: 505-21
37. Juhn SK, Hunter BA, Odland RM. Blood-labyrinth barrier and fluid dynamics of the inner ear. Int Tinnitus J 2001; 7: 72-83
38. Wangemann P. Supporting sensory transduction: cochlear fluid homeostasis and the endocochlear potential. J Physiol 2006; 576: 11-21
39. + absorption by outer sulcus epithelial cells. Hear Res 1999; 134: 48-56
40. Wangemann P. K(+) cycling and its regulation in the cochlea and the vestibular labyrinth. Audiol Neurootol 2002; 7: 199-205